Qkine secures funding to extend development of R&D pipeline and accelerate commercialisation of product portfolio
Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications has closed a further round of investment. The £550k funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018. Joining the original investors is biotech entrepreneur and founder member of the Cambridge Angels, Dr Andy Richards CBE.
Stem cells are revolutionising medicine by enabling new approaches for disease modelling, precision medicine and development of new therapeutics. University of Cambridge spin-out, Qkine, uses proprietary technologies and protein engineering techniques to produce exceptionally high purity growth factors and cytokines. Qkine’s technologies enable it to solve scientific challenges such as structural heterogeneity, poor stability and solubility and spurious interactions with other biomolecules, and provide more reliable tools for research and bio-manufacturing.
The investment enables Qkine to establish its UK manufacturing base at Cambridge Science Park, fuel the expansion of its research team and further develop its active R&D pipeline.